Concurrent Chemo-radiotherapy With IMRT for Stage I-III Small Cell Lung Cancer
Eligible patients (see below) will receive radiotherapy to the primary tumor and the
initially involved mediastinal lymph nodes on FDG-PET scan to a dose of 45Gy in 30 fractions
in 3 weeks (1.5Gy BID). Radiotherapy will be delivered concurrently with cisplatin (or in
case of a creatinin clearance of <60ml/min, carboplatin) and etoposide chemotherapy. When
after 4 cycles of chemotherapy and concurrent chest radiotherapy, no disease progression is
observed and the WHO performance status is 0-2, PCI (prophylactic cranial irradiation) will
bee offered to a dose of 25 Gy in 10 daily fractions.
The radiation doses will be specified according to ICRU 50. Lung density corrections will be
applied, as well as all standard QA procedures. Technical requirements are the same as in
standard practice at MAASTRO clinic.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Isolated nodal failures
Proportion of isolated nodal failures 18 months post-radiotherapy
Dirk De Ruysscher, MD, PhD
Netherlands: Dutch Health Care Inspectorate